Bihans Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 04-01-2025
- Paid Up Capital ₹ 0.10 M
as on 04-01-2025
- Company Age 7 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -70.68%
(FY 2022)
- Profit -92.13%
(FY 2022)
- Ebitda -18.65%
(FY 2022)
- Net Worth 27.25%
(FY 2022)
- Total Assets 17.82%
(FY 2022)
About Bihans Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Harikishan Sobti, Ankit Sobti, and Vipul Sobti serve as directors at the Company.
- CIN/LLPIN
U24304MH2017PTC289916
- Company No.
289916
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Jan 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Bihans Pharmaceuticals Private Limited offer?
Bihans Pharmaceuticals Private Limited offers a wide range of products and services, including Sexual Wellness Products, Fertility Enhancer, Anti Infective Drugs & Medicines, Antiviral Drugs, Common Disease Medicines, Eye Care Medicines, Pain Relief Drugs & Pharmaceuticals, Muscle Relaxant, Hair Growth Medicine, Brain & Nervous System Drugs.
Who are the key members and board of directors at Bihans Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ankit Sobti  | Director | 25-Jan-2017 | Current |
| Harikishan Sobti | Director | 25-Jan-2017 | Current |
| Vipul Sobti | Director | 14-Jun-2021 | Current |
Financial Performance of Bihans Pharmaceuticals.
Bihans Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 70.68% decrease. The company also saw a substantial fall in profitability, with a 92.13% decrease in profit. The company's net worth Soared by an impressive increase of 27.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bihans Pharmaceuticals?
In 2020, Bihans Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bihans Pharmaceuticals?
Unlock and access historical data on people associated with Bihans Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bihans Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bihans Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
